-
Hi, this is Nick Morris for the NCS
-
Podcast, and we are live at annual.
-
This is our wrap-up of today, and I'm
-
with some of the members of the NCS
-
Podcasts of Committee. Can we go around
-
and introduce ourselves? Sure. So,
-
I'm John Rosenberg. It's good to see
-
everyone. Cassie Hronfeld, I'm here
-
from Harbor, UCLA Stefan Mayer, past
-
president, and I work with John as well,
-
which is a true privilege. Well,
-
thanks, everybody, for joining us,
-
and I thought it would just be a nice
-
way to wrap up today by everyone going
-
around and sharing one highlight of the
-
meeting so far from. So, John, why
-
don't you get us started? Well, this
-
is actually my first day at NCS ever,
-
so it was nice to make it to the
-
conference and see my colleagues. Lots
-
of good learning I think for me, I did
-
enjoy the brain death talk and just kind
-
of under, I think, just understanding
-
and seeing how there's a lot of
-
heterogeneity and how. brain death is
-
declared and how people adhere to the
-
guidelines was a little kind of scary
-
for me, but also nice to see that the
-
society is taking this seriously and
-
that there are going to be new
-
guidelines coming out. What are those
-
guidelines going to sag, you know? No
-
CTA. And maybe I don't know what that's
-
going to look like That's under embargo.
-
I'm a big
-
CTA fan when the rare circumstance when
-
I have to get a confirmatory test
-
because it's like easier and faster,
-
you know? It's a 5 minute study.
-
French. Right? Out of the God.
-
All right, stuff on. What was you on
-
your highlights today? I'm thinking
-
about intrepid. But what was really
-
interesting? I'm ready for intrepid and
-
it was really fun today because it's a
-
true reveal. It's like drumroll,
-
please. But there's a little study of
-
50 febrile and our critical care
-
patients kind of sick, they're doing,
-
they have sustained fever and they give
-
half of them bromachryphine in addition
-
to standard of care. So they've already
-
been febrile for 24 hours after getting
-
like, you know, a thousand milligrams
-
Q6 of acetaminophen drumroll. It worked.
-
It was really impressive. There was a
-
really cool separation of the
-
temperature curves and it was also they
-
measured as an outcome escalation to
-
like, you know, a servo controlled
-
cooling device or something. And it was
-
less escalation, it was really cool.
-
You guys, it looks like you saw that,
-
Nick, right? I did, I loved it.
-
We've been using more and more
-
bromo-cryptine. I think there's another
-
recent paper that was published showing
-
it works. And I've become a believer.
-
And this, sometimes we kind of game the
-
system, right? I think it's good for
-
patient care, but it also can push
-
patient care along because of all the
-
procedures that get delayed because of
-
fever, right? The trachin peg that
-
gets pushed off, the transfer out of
-
the ICU or to rehab that gets pushed off
-
because they're spiking fever than
-
someone's concerned. And we know that
-
they seem to have these cyclic fevers
-
that once a day they spike a fever and
-
we're not gonna further work this up.
-
And that just goes away, I think, with
-
bromocarative. But I think what's kind
-
of cool is that if you, mostly when you
-
want to control febards in a
-
neuropatient, that's gonna segue to
-
intrepid, but the
-
neuropatients are different And a lot of
-
these savers are actually part of a
-
cocktail problems that we think of, we,
-
you know, classify storming. But I get
-
it totally, like, by suppressing the
-
storming, they look better, they look
-
less sick, and you can move them a lot
-
better. Yeah, and I guess you can keep
-
a fully in for 14 days and not increase
-
the risk of UTI. That was the big way
-
we were able to try. How they defined
-
UTI, you know, they ain't got to, but
-
they're like, most of their attention
-
is they don't look, right? You know,
-
no culture, right? I don't dislike way
-
off of that. So I guess my main
-
takeaway from the Intrepid report out,
-
and hopefully Dave Guru doesn't come me
-
down after this, was that we don't know
-
yet, is fever just a sign that the
-
patient's going to do poorly? And we
-
know fevers happen in brain injury, but
-
we just still don't know. Does
-
intervening on that fever change the
-
outcome? So I thought that was actually
-
really a good take back moment kind of,
-
you know, take a step back, reevaluate
-
what we're doing and say like, wait,
-
are we the wrong thing is the fever just
-
the sign of something else and it's not
-
really the key to the intervention.
-
Well and right the only main differences
-
in the two groups were the fever burden
-
and shivering which is like duh of
-
course right um but if if you control
-
fever without shivering that's that's
-
all another question it's out there
-
right and so um you know my my boss near
-
just been working on this for a while
-
only these intranasal devices and I
-
think that's uh still fair game is we
-
have to answer this question is how
-
deleterious is shivering and if there is
-
a way to control fever without shivering
-
is that worth pursuing maybe
-
bromocrypton is the answer I don't know
-
because the shiver on bromocrypton well
-
that's fine it's not part of the uh the
-
classic columbia stepwise you know to
-
shiver protocol which hats off to nary
-
she you know really came up with that
-
team effort obviously but that's I mean
-
presumably you're you're doing that
-
you're doing you know the magnesium Nipu
-
Speron.
-
and the skin counter-warming, and then
-
I love the duck-spent automating, right,
-
and, you know, so you don't have to,
-
it is true, like, if you zonk people.
-
I don't know if people know this, but
-
in the very beginning, when we were
-
doing TTM, we're pulling blankets and
-
catheters, they were going directly to
-
the parody, and that was it, and just
-
getting zonked, and extending the
-
length of stay, and getting more
-
pneumonias, and the whole thing, so.
-
Yeah, but they, we'll see the
-
publication, right? They will, they
-
will.
-
Any other thoughts about the meeting?
-
Yeah, it's just nice to be back in
-
person, this is my first meeting since
-
I graduated fellowship, really nice to
-
connect with people, and meet new
-
people as well. Yeah, Nick, what do
-
you think of the weather? It's hot,
-
it's real hot, it's not a little hot,
-
it's hotter than hot We walked two
-
blocks to get tacos and I was sweating.
-
my shirt and before I even got there.
-
But John, your family's from here.
-
We're from New York, moved here about
-
2000, about 20 years ago. But this is
-
a hot time. The weather's going to
-
break. And typically also in Phoenix,
-
it's in a valley and it's also a lot of
-
concrete. So it's a little warmer here
-
than the rest of like, you know, if
-
you go a little further north, you know,
-
maybe 105, not 110 or 100, not 110.
-
Well, this is why NCS usually is in
-
October, right? So we picked a really
-
good time of year. I hope we're going
-
back.
-
Well,
-
no, no news there is hot in Phoenix,
-
but really exciting studies that were
-
released today, new results at NCS,
-
which is unusual for us. And I think
-
moving this conference a step forward
-
and its importance is getting results
-
from a major trial like Intrepid for the
-
first time. So that's really exciting.
-
And hopefully there'll be more of that
-
in the future at the neurocritical care
-
and no meeting. you guys are going to
-
do one bar drain. We've already started
-
one bar drains. We have done over 80
-
patients. We started before the early
-
drain trial was released. We talked
-
about on the podcast earlier today.
-
We've changed a little bit of our
-
protocol based on the early drain
-
protocol because we did have some safety
-
concerns with some brain sag from over
-
drainage. And I think this dual
-
measurement looking for a gradient
-
between the EVD and the one bar drain
-
pressures helps protect against that.
-
So we're going to start as well. It's a
-
lot of interest.
-
All right. Well, thanks everybody.
-
Keep tuning in to live at annual for
-
your updates on the annual neurocritical
-
care conference. We're excited to bring
-
this content to you and we hope you'll
-
keep downloading the NCS podcast
-
wherever you get your podcasts.